The University of Texas MD Anderson Cancer Center and Pfizer have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
US pharma giant Pfizer has spun off four investigational drugs into a new medicines company, dubbed SpringWorks Therapeutics.
Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
AstraZeneca has announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.
Vanda Pharmaceuticals announced results from an eight-week randomized phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis.
AstraZeneca and MedImmune have presented the full PFS data from a planned interim analysis of the phase III PACIFIC trial.
IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).
AstraZeneca’s Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) has met its primary endpoints in the Phase III Amplify trial of patients with chronic obstructive pulmonary disease (COPD).
Cancer Research UK has launched a clinical study to evaluate a new cancer drug in patients with advanced solid tumours in four centres across the UK through its Centre for Drug Development.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.